FAQ

Q:  How long does it take to approve a cancer therapeutic on average?
A:  On average it takes 15 years and over $1.2 B for a pharmaceutical company to bring a cancer therapeutic to the market.
Q:  What is the Valley of Death?
A:  The Valley of Death refers to the time and financial risks that start-ups face as they struggle to grow from small teams to going ventures.  In the context of cancer, it refers to the time and money required to turn basic lab research and discoveries into treatments that help people.  Much of the valley of death is caused by regulatory burden.
Q:  What is the invisible graveyard?
A:  The invisible graveyard refers to the hundreds of thousands of people each year that die from cancer while awaiting a cure.
Q:  What is a Randomized Controlled Trial (RCT)?
A:  RCT is a method of scientific study where the subjects are “randomized” into a group that takes the drug under investigation and a group that is taking placebo or standard of care.  In cancer, this is particularly questionable from an ethics perspective.  If faced with a terminal illness, it should be your choice to take an experimental therapy.
Q:  Is there a silver bullet to cure cancer?
A:  NO!  There is no silver bullet.  Cancer manifests itself differently from one person to another and is a multi-faceted disease.  The opportunity to find a cure lies in the ability for practitioners to combine therapies to shut down all of the affected pathways, not just a single one.

 

Donate Now

Your contribution will help Fight to Live
continue to drive public awareness, grow
the coalition, and organize activities and
actions that members can participate in.
Contributions will also help continue its
efforts and advocacy in Washington DC,
informing congressional staff of the dire
need for continual investment in new
therapies alongside a more streamlined,
efficient approval process.